Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Application of serum anti-Müllerian hormone levels in selecting patients with polycystic ovary syndrome for in vitro maturation treatment

  • Seok, Hyun Ha (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Song, Haengseok (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Lyu, Sang Woo (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Kim, You Shin (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Lee, Dong Ryul (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Lee, Woo Sik (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Yoon, Tae Ki (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University)
  • Received : 2016.02.04
  • Accepted : 2016.02.26
  • Published : 2016.06.23
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study was to identify useful clinical factors for the identification of patients with polycystic ovary syndrome (PCOS) who would benefit from in vitro maturation (IVM) treatment without exhibiting compromised pregnancy outcomes. Methods: A retrospective cohort study was performed of 186 consecutive patients with PCOS who underwent human chorionic gonadotropin-primed IVM treatment between March 2010 and March 2014. Only the first IVM cycle of each patient was included in this study. A retrospective case-control study was subsequently conducted to compare pregnancy outcomes between IVM and conventional in vitro fertilization (IVF) cycles. Results: Through logistic regression analyses, we arrived at the novel finding that serum $anti-M{\ddot{u}}llerian$ hormone (AMH) levels and the number of fertilized oocytes in IVM were independent predictive factors for live birth with unstandardized coefficients of 0.078 (95% confidence interval [CI], 1.005-1.164; p=0.037) and 0.113 (95% CI, 1.038-1.208; p=0.003), respectively. Furthermore, these two parameters were able to discriminate patients who experienced live births from non-pregnant IVM patients using cut-off levels of 8.5 ng/mL and five fertilized oocytes, respectively. A subsequent retrospective case-control study of patients with PCOS who had serum AMH levels ${\geq}8.5ng/mL$ showed that IVM had pregnancy outcomes comparable to conventional IVF, and that no cases of ovarian hyperstimulation syndrome were observed. Conclusion: Serum AMH levels are a useful factor for predicting pregnancy outcomes in PCOS patients before the beginning of an IVM cycle. IVM may be an alternative to conventional IVF for PCOS patients if the patients are properly selected according to predictive factors such as serum AMH levels.

Keywords

References

  1. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-74. https://doi.org/10.1530/eje.0.1380269
  2. Chian RC. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online 2004;8:547-52. https://doi.org/10.1016/S1472-6483(10)61101-7
  3. Smith V, Osianlis T, Vollenhoven B. Prevention of ovarian hyperstimulation syndrome: a review. Obstet Gynecol Int 2015;2015:514159.
  4. Nastri CO, Teixeira DM, Moroni RM, Leitao VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol 2015;45:377-93. https://doi.org/10.1002/uog.14684
  5. Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121-8. https://doi.org/10.1007/s10815-010-9387-6
  6. Tiitinen A, Husa LM, Tulppala M, Simberg N, Seppala M. The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102:326-9. https://doi.org/10.1111/j.1471-0528.1995.tb09140.x
  7. Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991;55:109-13. https://doi.org/10.1016/S0015-0282(16)54068-0
  8. Das M, Son WY, Buckett W, Tulandi T, Holzer H. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome. Reprod Biomed Online 2014;29:545-51. https://doi.org/10.1016/j.rbmo.2014.07.019
  9. Shalom-Paz E, Holzer H, Son W, Levin I, Tan SL, Almog B. PCOS patients can benefit from in vitro maturation (IVM) of oocytes. Eur J Obstet Gynecol Reprod Biol 2012;165:53-6. https://doi.org/10.1016/j.ejogrb.2012.07.001
  10. Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 2001;76:936-42. https://doi.org/10.1016/S0015-0282(01)02853-9
  11. Child TJ, Sylvestre C, Pirwany I, Tan SL. Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes. Hum Reprod 2002;17:1997-2002. https://doi.org/10.1093/humrep/17.8.1997
  12. Gremeau AS, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, et al. In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertil Steril 2012;98:355-60. https://doi.org/10.1016/j.fertnstert.2012.04.046
  13. Chang EM, Han JE, Seok HH, Lee DR, Yoon TK, Lee WS. Insulin resistance does not affect early embryo development but lowers implantation rate in in vitro maturation-in vitro fertilization-embryo transfer cycle. Clin Endocrinol (Oxf) 2013;79:93-9. https://doi.org/10.1111/cen.12099
  14. Mikkelsen AL, Andersson AM, Skakkebaek NE, Lindenberg S. Basal concentrations of oestradiol may predict the outcome of in-vitro maturation in regularly menstruating women. Hum Reprod 2001;16:862-7. https://doi.org/10.1093/humrep/16.5.862
  15. Fadini R, Comi R, Mignini Renzini M, Coticchio G, Crippa M, De Ponti E, et al. Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment. J Assist Reprod Genet 2011;28:501-8. https://doi.org/10.1007/s10815-011-9589-6
  16. Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002;100:665-70.
  17. Tan SL, Child TJ. In-vitro maturation of oocytes from unstimulated polycystic ovaries. Reprod Biomed Online 2002;4 Suppl 1:18-23.
  18. Guzman L, Ortega-Hrepich C, Polyzos NP, Anckaert E, Verheyen G, Coucke W, et al. A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count. Hum Reprod 2013;28:1261-6. https://doi.org/10.1093/humrep/det034
  19. Kedem A, Yerushalmi GM, Maman E, Hemi R, Hanochi M, Hourvitz A. What is the optimal threshold of serum Anti-Mullerian hormone (AMH) necessary for IVM treatments? J Assist Reprod Genet 2013;30:745-51. https://doi.org/10.1007/s10815-013-9996-y
  20. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014;20:688-701. https://doi.org/10.1093/humupd/dmu020
  21. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96. https://doi.org/10.1093/humupd/dmg005
  22. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197-203. https://doi.org/10.1007/s10815-011-9627-4
  23. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006;85:1541-3. https://doi.org/10.1016/j.fertnstert.2005.10.052
  24. Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014;211:59.e1-8. https://doi.org/10.1016/j.ajog.2014.02.026
  25. Cha KY, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005;83:1461-5. https://doi.org/10.1016/j.fertnstert.2004.11.044
  26. Lin YH, Hwang JL, Huang LW, Mu SC, Seow KM, Chung J, et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 2003;18:1632-6. https://doi.org/10.1093/humrep/deg335
  27. Shavit T, Ellenbogen A, Michaeli M, Kartchovsky E, Ruzov O, Shalom- Paz E. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined? Eur J Obstet Gynecol Reprod Biol 2014;179:46-50. https://doi.org/10.1016/j.ejogrb.2014.05.013
  28. Walls ML, Hunter T, Ryan JP, Keelan JA, Nathan E, Hart RJ. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod 2015;30:88-96. https://doi.org/10.1093/humrep/deu248

Cited by

  1. Predictive factors for live birth after in vitro maturation of oocytes in women with polycystic ovary syndrome vol.297, pp.1, 2016, https://doi.org/10.1007/s00404-017-4561-z
  2. The Place of In Vitro Maturation in PCO/PCOS vol.2018, pp.None, 2016, https://doi.org/10.1155/2018/5750298
  3. Evaluating the effects of administration of 25-hydroxyvitamin D supplement on serum anti-mullerian hormone (AMH) levels in infertile women vol.34, pp.5, 2016, https://doi.org/10.1080/09513590.2017.1410785
  4. Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome vol.11, pp.None, 2018, https://doi.org/10.1186/s13048-018-0445-5
  5. Successful live birth after in vitro maturation treatment in a patient with autoimmune premature ovarian failure: a case report and review of the literature vol.37, pp.12, 2016, https://doi.org/10.1080/09513590.2021.1928065